Overview

Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Helicobacter pylori (H. pylori) eradication is achieved in 60-80% with first-line therapy. Different second-line therapeutic options are available. However, the success of second-line therapy has not been addressed or reported from Saudi Arabia. Objectives The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment.
Phase:
N/A
Details
Lead Sponsor:
King Faisal Specialist Hospital & Research Center
Treatments:
Doxycycline
Esomeprazole
Levofloxacin
Ofloxacin